

- Monoamine oxidase inhibitors (MAOIs)
 action of, 465e-2
 adverse effects of, 1617t, 2392, 2710t, 2717
 for depression, 2710t, 2717
 drug interactions of, 246e-4t, 246e-9, 2711t, 2717
 overdose/poisoning with, 473e-8t, 473e-13t
 for panic disorder, 2709
- Monoamine oxidase type B (MAO-B) inhibitors, 2615, 2616t
- Monobactams. *See* Aztreonam
- Monoblasts, 421
- Monoclonal cryoglobulinemia, 368
- Monoclonal gammopathy, malignant, 618–619, 712. *See also* B-cell chronic lymphoid leukemia (CLL)/small lymphocytic lymphoma; Multiple myeloma; Waldenström's macroglobulinemia
- Monoclonal gammopathy of undetermined significance (MGUS)
 amyloidosis in, 721
 diagnosis of, 714–715, 715t
 features of, 103e-2
 in HIV infection, 1262
 polyneuropathy in, 2696t, 2699, 2700
 tumor markers in, 473t
 von Willebrand disease in, 731
- Monoclonal immunoglobulin, 473t
- Monocyte(s), 421
 disorders of, 419t, 421–422
 hematopoietic differentiation of, 89e-3f
 in HIV infection, 1238
 in peripheral blood smear, 81e-2, 81e-6f
 in tuberculosis, 1107
- Monocyte chemotactic protein-1 (MCP-1), 372e-11t
- Monocyte chemotactic protein-2 (MCP-2), 372e-11t
- Monocyte chemotactic protein-3 (MCP-3), 372e-12t
- Monocyte chemotactic protein-4 (MCP-4), 372e-12t
- Monocyte chemotactic proteins (MCPs), 1242
- Monocytoid B-cell lymphoma, 707
- Monocytosis, 421
- Monogenic disorders. *See* Mendelian disorders
- Monokine induced by IFN- γ (MIG), 372e-12t
- Mononeuropathies, 463e-4–5, 463e-5f, 1124, 2691–2692
- Monongahela virus, 1308t
- Monoparesis, 157
- Monopotent cells, 454
- Monosodium glutamate, 216
- Montelukast
 adverse effects of, 2218t
 for allergic rhinitis, 2122, 2123f, 2124
 for angioedema, 2119
 for asthma, 1678
 for urticaria, 2119
- Mood disorders, 2714
 alcohol-induced, 2725
 bipolar disorder. *See* Bipolar disorder
 depression. *See* Depression/depressive disorders
 in fibromyalgia, 2239
 in the homeless, 2723
 neuropathology of, 465e-3–4, 465e-4f
- Mood stabilizers, 2718t. *See also* specific drugs
- Moral distress, 17e-2–3
- Moral hazard, 15e-2–3
- Moraxella catarrhalis*, 150e-2t, 1013, 1014
- Moraxella catarrhalis* infections
 clinical features of, 1013
 hemoptysis, 245
 laryngitis, 234
 mastoiditis, 231
 otitis media, 229–230, 1013
 pneumonia, 1013
 sinusitis, 226, 1013
 in COPD, 1013, 1014f
 diagnosis of, 1013–1014
 epidemiology of, 1013
 pathogenesis of, 1013
 treatment of, 230, 1014
- Morbilloform eruptions. *See also* Rash
 definition of, 340t
 drug-induced, 377–378, 380–381, 381f
 etiology of, 362, 362t
- Morganella* infections, 862, 1035
- Morgellons syndrome, 2750–2751
- Moricizine, 1479t
- Morphea, 355, 355t, 376
- Morphine
 adverse effects of, 1603, 1741, 2640t
 for autonomic storm, 2643
 dosage in liver disease, 37
 for dyspnea, 47e-4, 62t
 in mechanical ventilation, 1741
 for myocardial infarction, 1597t, 1603
 for pain, 60, 91t, 92
 for pulmonary edema, 1761f, 1763
 routes of administration of, 92
 for sickle cell painful crisis, 635
 sustained-release, 91t, 94
 during terminal weaning, 67
 therapeutic monitoring of, 2765t
- Morquio syndromes, 432e-2t
- Mortality. *See* Death
- Mortality rates, 93e-2. *See also* specific diseases
- Morumbi virus, 1309t
- Morvan's syndrome, 617, 619
- Mosaicism, 432, 439
- Mosquito(s)
Aedes. *See Aedes* mosquitos
 in arboviral encephalitis, 1314–1317
 bite, 2749–2750
Culex. *See Culex* mosquitos
 in malaria transmission, 1368–1370, 1369f, 1371
- Mother's curse, in aging, 94e-3
- Motherwort, 404t
- Motilin agonists, 260t
- Motion sickness, 62, 259, 260, 260t
- Motor cortex, 176f
- Motor efferents, 47e-1
- Motor evoked potentials, 442e-3–4
- Motor examination, 2538
- Motor neuron disorders. *See also* Amyotrophic lateral sclerosis (ALS)
 differential diagnosis of, 2633
 etiology of, 2631t
 genetic, 2634–2635t
 lower, 2632t, 2634t, 2635–2636
 sporadic, 2632t
 upper, 2632t, 2634–2635t, 2636
- Motor neurons, age-related changes in, 76
- Motor neuropathy, 618, 2699
- Motor tic, 2623
- Mounier-Kuhn syndrome, 1695
- Mountain sickness, chronic, 248, 476e-5
- Mouth
 dry. *See* Xerostomia
 healthy, 46e-3f
- Mouth-to-mouth resuscitation, 1769
- Movement disorders
 choreas. *See* Chorea(s)
 drug-induced, 2624
 dystonia. *See* Dystonia
 Huntington's disease. *See* Huntington's disease
 hyperkinetic. *See* Hyperkinetic movement disorders
 myoclonus. *See* Myoclonus
 in neurodegeneration with brain iron accumulation, 2625–2626
 in Parkinson's disease. *See* Parkinson's disease
 in pregnancy, 49
 psychogenic, 2626
 restless legs syndrome. *See* Restless legs syndrome
 Tourette's syndrome, 2623
 in Wilson's disease. *See* Wilson's disease
- Moxifloxacin
 action of, 931t, 932–933
 adverse effects of, 943
 for anaerobic bacterial infections, 1101
 for community-acquired pneumonia, 767t, 808t
 for febrile neutropenia, 103e-23
- for health care-associated pneumonia, 812t
 indications for, 941t, 943
 for *Legionella* infections, 1020t
 for leprosy, 1126
 for lung abscess, 815
 for mucopurulent cervicitis, 876
 for multidrug-resistant TB, 205e-6
 for pelvic inflammatory disease, 878
 for plague, 1075
 for pneumonia, 953
 resistance to, 931t, 941t, 1101
 for sinusitis, 227t
- Moxonidine, 1513
- Moyamoya disease, 441e-41f, 2568, 2584
- 6-MP. *See* 6-Mercaptopurine (6-MP)
- MPN-U (myeloproliferative neoplasm, unclassifiable), 135e-6–7
- M protein, 964
- MPTP, 444e-3, 2611
- MRA. *See* Magnetic resonance angiography (MRA)
- MRCP. *See* Magnetic resonance cholangiopancreatography (MRCP)
- MRE11* gene, 375e-1, 2109
- MRF (myelin gene regulatory factor), 444e-5
- MRI. *See* Magnetic resonance imaging (MRI)
- MRP2 (multidrug resistance-associated protein 2), 2000
- MRP3 (multidrug resistance-associated protein 3), 2000
- MRSA infections. *See* Methicillin-resistant *Staphylococcus aureus* (MRSA) infections
- MS. *See* Multiple sclerosis (MS)
- MSA. *See* Multiple system atrophy (MSA)
- MSCRAMMs, 145e-7, 817, 955–956, 972
- MSH. *See* α -Melanocyte-stimulating hormone (MSH)
- MSH2* gene mutations, 101e-6t, 538t, 592, 596
- MSH6* gene mutations, 101e-6t
- MSM. *See* Men who have sex with men (MSM)
- MSMD (Mendelian susceptibility to mycobacterial disease), 2106
- MTC. *See* Medullary thyroid carcinoma (MTC)
- MTD (maximum-tolerated dose), 103e-5
- mtDNA. *See* Mitochondrial DNA (mtDNA)
- 5-MTHF (5,10-methylenetetrahydrofolate), 641, 641t
- MTHFR (methylenetetrahydrofolate reductase), 47, 641t, 642f, 643, 744
- mTOR, 94e-5, 103e-16f, 562, 1701
- mTOR inhibitors, 102e-3, 103e-19, 119e-4, 562, 1853. *See also* Everolimus; Temsirolimus
- Mucambo virus, 1306t
- Muckle-Wells syndrome (MWS)
 amyloidosis in, 1845
 clinical features of, 372e-8t, 2213t, 2215
 genetic considerations in, 2213t
 pathogenesis of, 372e-8t
 treatment of, 2213t
- Mucociliary elevator, 949
- Mucopolidoses, 432e-3t
- Mucopolysaccharidoses, 432e-2t, 432e-5–6, 436e-5f, 1565
- Mucorales, 1350, 1351. *See also* Mucormycosis
- Mucormycosis, 1350
 clinical features of, 135, 226, 784, 1350–1351
 diagnosis of, 1351, 1351f
 differential diagnosis of, 1351–1352
 epidemiology of, 1350
 etiology of, 1350, 1350t
 in HIV infection, 1250
 in immunocompromised patient, 76e-12f, 489, 489t
 pathogenesis of, 1350
 in transplant recipient, 925, 926
 treatment of, 1352–1353, 1352t
- Mucosa-associated lymphoid tissue (MALT), 372e-23, 372e-25f
- Mucosa-associated lymphoid tissue (MALT) lymphoma, 703
 clinical features of, 535–536, 702t, 703
 diagnosis of, 703